PROPHASE LABS, INC. (NASDAQ:PRPH) Files An 8-K Changes in Registrant’s Certifying Accountant

PROPHASE LABS, INC. (NASDAQ:PRPH) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01.

On December 10, 2020 (the “Dismissal Date”), the Audit Committee of the Board of Directors of ProPhase Labs, Inc. (the “Company”) dismissed EisnerAmper LLP (“EisnerAmper”) as the Company’s independent registered public accounting firm.

The reports of EisnerAmper on the audited consolidated financial statements of the Company as of and for the years ended December 31, 2019 and 2018, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

During the years ended December 31, 2019 and 2018 and through the Dismissal Date, there were no disagreements with EisnerAmper on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of EisnerAmper, would have caused it to make reference thereto in its reports on the audited consolidated financial statements of the Company for such years. During the years ended December 31, 2019 and 2018, and through the Dismissal Date, there were no “reportable events” as defined under Item 304(a)(1)(v) of Regulation S-K, except for the material weakness described in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2018 (as amended), which was remediated as of December 31, 2019.

The Company provided EisnerAmper with a copy of the disclosures it is making herein in response to Item 304(a) of Regulation S-K, and requested that EisnerAmper furnish the Company with a letter addressed to the Securities and Exchange Commission (the “SEC”), to Item 304(a)(3) of Regulation S-K, stating whether or not it agrees with the statements related to EisnerAmper made by the Company in this report. A copy of EisnerAmper’s letter to the SEC dated December 14, 2020 is attached as Exhibit 16.1 to this report.

Also on December 10, 2020, the Audit Committee recommended and approved the selection of Friedman LLP (“Friedman”) as the Company’s new independent registered public accounting firm.

During the years ended December 31, 2019 and 2018, and through the Dismissal Date, neither the Company, nor anyone on its behalf, consulted Friedman regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the audited consolidated financial statements of the Company, and no written report was provided to the Company or oral advice was provided that Friedman concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).

(d) Exhibits

No. Description
16.1 Letter from EisnerAmper LLP to the Securities and Exchange Commission, dated December 14, 2020.


ProPhase Labs, Inc. Exhibit
EX-16.1 2 ex16-1.htm   Exhibit 16.1   December 14,…
To view the full exhibit click here

Story continues below

About PROPHASE LABS, INC. (NASDAQ:PRPH)

ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a range of homeopathic and health products. The Company is also engaged in the research and development of over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. It is engaged in manufacturing, distributing, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. It also manufactures, markets and distributes an organic cough drop and a Vitamin C supplement, Organix, and performs contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties. Its product pipeline includes Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray. It also produces Legendz XL for sexual health, Triple Edge XL, which is a daily energy booster plus testosterone support, and Super ProstaFlow Plus for prostate and urinary health.

An ad to help with our costs